One In, One Out: Mirum Seeks New EU Indication For Maralixibat, Withdraws Another
Kyowa Kirin And Sanofi Want CHMP To Re-Examine Earlier Opinion About Their Products
Sponsors of three drugs have withdrawn their EU marketing authorization applications in the middle of the assessment process, including one for a bladder cancer therapy that was recently turned down in the US.
